Exploring Advanced Approaches for the Isolation and Detection of Exosomes as Biomarkers for Prostate Cancer

The exosomes technology has emerged as a promising alternative to traditional diagnostic methods with potential advantages in detecting prostate cancer. Given the increasing incidence of prostate cancer, especially among older men, there is a strong need for non-invasive, accurate and efficient diagnostic tools. The paper aims to explore the potential of exosomes as biomarkers for prostate cancer, evaluate their application in early diagnosis and therapeutic monitoring of prostate cancer, and compare existing isolation and detection techniques. By examining recent advances in exosome isolation and detection technologies, the application of technologies such as immunocapture, nanoparticle tracking assay (NTA) and microfluidic platforms in prostate cancer detection is highlighted. Also, the detection performance of relevant biomarkers, such as prostate-specific antigen (PSA) and Survivin, in exosomes is evaluated. The results indicate that exosomes, exosomes secreted by tumor cells carry a variety of biomolecules, which can markedly boost the sensitivity and specificity of prostate cancer diagnosis when compared to the traditional PSA test. And specific exosomal biomarkers have been shown to be effective biomarkers for the early diagnosis of prostate cancer. Despite the advantages of exosome technology, several challenges remain, including the standardization of methods, the improvement of sensitivity, and the regulation of this field. It is recommended that future studies optimize separation, improve sensitivity, and develop standardized platforms to facilitate prostate cancer detection and improve patient prognosis.